Drug Profile
Sildenafil - Pfizer
Alternative Names: Revatio; Revatio IV; Sildenafil citrate; Sildenafil Citrate ODF - Pfizer; Sildenafil citrate orally-disintegrating film - Pfizer; UK 92480; ViagraLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; University of Calgary
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erectile dysfunction; Pulmonary arterial hypertension
- Phase III Diastolic heart failure; Heart failure; Pulmonary hypertension
- No development reported Female infertility; Raynaud's disease
- Discontinued Angina pectoris; Cardiovascular disorders; Eye disorders; Female sexual dysfunction; Meniere's disease
Most Recent Events
- 06 Sep 2022 No development reported - Phase-III for Pulmonary hypertension (In neonates) in France (IV) (NDR Batch 23)
- 14 Jun 2022 Pfizer completes the investigator-sponsored phase III SilHF trial in Heart failure (Treatment-experienced) in United Kingdom, Israel, Italy and Norway (NCT01616381)
- 28 Sep 2020 Pfizer completes a phase III trials in Pulmonary Hypertension (In infants, In neonates) in Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, UK and USA (IV) (NCT01720524)